In a news release, Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) presented a summation of its plans for clinical studies during 2021.
Algernon Pharmaceuticals reported that has plans to establish at least one and possibly a second new clinical research program in Q1/20 with the objective of beginning either Phase 1 or Phase 2 clinical trial(s) prior to year-end for new disease indication(s). The firm advised that potential target compounds include drugs that it has already investigated in preclinical animal models or other compounds the company has been reviewing that demonstrate potential for preclinical and perhaps clinical efficacy for a new disease indication.
Algernon stated that "the focus will be on off patent compounds that are already approved in limited markets, but have not been approved in the U.S. or Europe and may include natural occurring compounds that have shown potential as new therapeutic treatments for serious global diseases."
The company noted that it may choose to advance certain compounds for rare orphan diseases. The firm pointed out that the U.S. Food and Drug Administration (FDA) and the European Union respectively provide 7 and 10 years of market exclusivity to medicines addressing some designated orphan disease indications. The company added that it may also wish to pursue new drug applications (NDAs) for products containing chemical entities never previously approved by the FDA either alone or in combination as these would garner a 5-year period of exclusivity.
The firm commented that it is presently working to increase enrollment in its idiopathic pulmonary fibrosis (IPF) and chronic cough clinical research program for NP-120 (ifenprodil). The company stated that the study had experienced delays in patient enrollment rates due to COVID-19, but it is now endeavoring to expand access to the clinical trials for additional patients in Australia and New Zealand. Algernon said that if the final study data is positive, it will then make a determination as to the best path forward whether to be filing a Pre-Investigational New Drug application with the FDA for IPF, chronic cough or both.
The company provided an update on the status of its Phase 2b/3 clinical research study of Ifenprodil for use in treatment of COVID-19. The firm advised that it expects that the final data set from the Phase 2b part of the trial will be available by the end of February 2021. Algernon stated that if the resulting data proves to be positive it intends to consult with the FDA on obtaining Emergency Use Authorization (EUA). The company said that it will be reviewing and interpreting the Phase 2b data in order to best structure the required Phase 3 program even if the FDA does not grant an EUA.
Algernon Pharmaceuticals' CEO Christopher J. Moreau commented, "The Company is in a unique position to leverage its capabilities in identifying compounds for repurposing and managing clinical trials, and to advance additional compounds into clinical studies in a timely and cost-effective manner...Our Chief Science Officer Dr. Mark Williams and I have stated many times that one of our key corporate goals was to have multiple compounds in clinical trials at the same time in order to improve our chances of a success, and that is what we intend to achieve."
Read what other experts are saying about:
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Algernon Pharmaceuticals. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon Pharmaceuticals, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
